STOCK TITAN

HAEMONETICS (HAE) SEC Filings, Jun-Jul 2025

HAE NYSE

Haemonetics Corporation filings document current-report disclosures for a Massachusetts medical technology company focused on hospital, plasma collection and blood center products. Recent Form 8-K filings cover quarterly and annual operating results, furnished earnings releases, and Regulation FD disclosures related to corporate responsibility reporting and capital-structure events.

The company’s filings also record governance and board matters, including director and committee disclosures tied to annual meeting processes. Material-event reports document financing and corporate actions such as repayment of convertible senior notes and the completed acquisition of Vivasure Medical Limited, a percutaneous vessel closure technology company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
insider
-
Form 8-K
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
current report
Rhea-AI Summary

Haemonetics Corporation Form 144 Notice details a proposed sale of 18,630 shares of common stock with an aggregate market value of $1,396,132.20 through Fidelity Brokerage Services on the NYSE, planned for June 26, 2025.

The shares were acquired through multiple restricted stock vestings between 2020-2025:

  • 2020-2022: 469 shares total from two vestings
  • 2023: 4,455 shares from three vestings
  • 2025: 13,706 shares from four recent vestings

The filing also discloses a previous sale by Josep L. Llorens of 1,547 shares on May 19, 2025, generating proceeds of $107,319.26. All shares were acquired as compensation through restricted stock vestings, representing approximately 0.04% of the total 48,036,996 shares outstanding.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
other

FAQ

How many HAEMONETICS (HAE) SEC filings are available on StockTitan?

StockTitan tracks 64 SEC filings for HAEMONETICS (HAE), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for HAEMONETICS (HAE)?

The most recent SEC filing for HAEMONETICS (HAE) was filed on November 13, 2026.